Fosun Pharma
Fosun Pharma, officially known as Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is a leading global healthcare company headquartered in China. Established in 1994, the firm has expanded its operations across major regions, including Asia, Europe, and North America, positioning itself as a key player in the pharmaceutical and healthcare industry. Fosun Pharma focuses on research and development, manufacturing, and distribution of innovative medicines, vaccines, and medical devices. Its core products, which include a diverse range of therapeutic solutions, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, including strategic partnerships and acquisitions that enhance its market presence. With a strong emphasis on innovation and a robust pipeline, Fosun Pharma continues to solidify its position as a prominent force in the global healthcare landscape.
DitchCarbon Score
How does Fosun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fosun Pharma's score of 55 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fosun Pharma's reported carbon emissions
In 2023, Fosun Pharma reported total carbon emissions of approximately 960,864,000 kg CO2e, with Scope 1 emissions at about 210,819,000 kg CO2e, Scope 2 emissions at approximately 677,874,000 kg CO2e, and Scope 3 emissions reaching about 72,171,000 kg CO2e. This marks a continued commitment to transparency in their emissions reporting. Fosun Pharma has set ambitious reduction targets, aiming for a 15% reduction in carbon emission intensity by 2025 compared to 2020 levels, which translates to a target of 0.23 tonnes CO2e per RMB 10,000 in revenue. Additionally, they plan to reduce comprehensive energy consumption intensity by 10% in the same timeframe, targeting 2.287 GJ per RMB 10,000 in revenue. Looking towards the long term, Fosun Pharma is aligned with the International Energy Agency's goal of achieving net zero emissions by 2050, demonstrating their commitment to sustainability across all scopes of emissions. This strategic approach reflects their dedication to addressing climate change and reducing their environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fosun Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
